Passage Bio, Inc. (PASG)

Compare

0.3619

-0.0471

(-11.52%)

At close: 4:00:01 PM EDT

0.3799

+0.02

+(4.97%)

After hours: 5:00:04 PM EDT

Passage Bio (PASG) Upgraded to Buy: Here's What You Should Know

Passage Bio (PASG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks last month

PASG
-11.52%
Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights

Interim data from Dose 1 PBFT02 demonstrated durable, elevated CSF PGRN and early evidence of reduction in plasma NfL levels, a disease progression biomarker, as compared to published natural history Enrolled first FTD-GRN patient to be treated with Dose 2 PBFT02, 50% lower than Dose 1 Expect to report 12-month data from Dose 1 and interim safety and biomarker data from Dose 2 in 2H 2025; plan to seek regulatory feedback on FTD-GRN pivotal trial design in 1H 2026 Extended cash runway into 1Q 202

GlobeNewswire last month

PASG
-11.52%
Passage Bio to Participate in Upcoming Investor Conferences

PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced management will participate in the following upcoming investor conferences: TD Cowen 45th Annual Health Care ConferenceFormat: Management will participate in a presentation and investor meetingsDate: Wednesday, March 5, 2025Presentation Time: 9:10 a.m. ETLocation: Boston, MA Leerink

GlobeNewswire last month

PASG
-11.52%
Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates

PBFT02 demonstrated durable, elevated CSF PGRN levels and early evidence of reduction in plasma NfL levels, a disease progression biomarker, compared to published natural history data Evaluating Dose 2, 50% lower than Dose 1, in subsequent FTD-GRN and FTD-C9orf72 patients to allow for dose exploration and support regulatory strategy Expect to report 12-month data from Dose 1 and interim safety and biomarker data from Dose 2 in 2H 2025; plan to seek regulatory feedback on FTD-GRN pivotal trial de

GlobeNewswire 2 months ago

PASG
-11.52%
Will Passage Bio (NASDAQ:PASG) Spend Its Cash Wisely?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Simply Wall St. 3 months ago

PASG
-11.52%
Passage Bio assumed with an Outperform at Wedbush

Wedbush assumed coverage of Passage Bio (PASG) with an Outperform rating and price target of $4, up from $3. Market sentiment may be different from the days when an extensive gene therapy pipeline of four programs and additional options to license IND-enabling research from UPenn supported Passage’s upsized IPO, but the current valuation looks to be a “deep discount” compared to the potential that PBFT02 for frontotemporal dementia can achieve, the analyst tells investors. Published first on The

TipRanks 4 months ago

PASG
-11.52%
Update: Wedbush Raises Price Target on Passage Bio to $4 From $3, Keeps Outperform Rating

(Updated to include Wedbush's commentary) Wedbush has increased its price target for Passage Bio

PREMIUM
MT Newswires 4 months ago

PASG
-11.52%
Passage Bio Achieves Milestones in Gene Therapy Trials

Passage Bio ( (PASG) ) has issued an update. Passage Bio, a genetic medicines company, reported significant progress in their PBFT02 gene therapy trials for FTD-GRN, revealing promising interim data that shows potential as a leading progranulin-raising therapy. With patient enrollment on track and robust preclinical data presented at key scientific conferences, the company is poised to achieve critical milestones, supported by a strong financial position ensuring operations until mid-2026. This

TipRanks 4 months ago

PASG
-11.52%
Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights

Enrolled 4 patients in Cohort 2 of the upliFT-D trial for FTD-GRN, with patient dosing advancing as planned; 12-month Cohort 1 and interim Cohort 2 data expected in 1H25 Updated interim data from Cohort 1 FTD-GRN showed PBFT02 was generally well-tolerated and elevated CSF progranulin levels for up to 12 months following treatment Highlighted robust preclinical data supporting PBFT02 as a potential best-in-class progranulin-raising therapy in an oral presentation at ESGCT Execution backed by stro

GlobeNewswire 4 months ago

PASG
-11.52%
Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference

PHILADELPHIA , Nov. 06, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will present at Guggenheim Securities Healthcare Innovation Conference on Wednesday, November 13, 2024 at 2:30 p.m. ET. A live webcast of the event will be available on the Investors & Media section of Passage Bio’s websi

GlobeNewswire 5 months ago

PASG
-11.52%
Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference

Preclinical data demonstrated that an AAV1 vector achieved superior human progranulin levels in the CSF as compared to AAV5 and AAVhu68 (an AAV9 variant) Nonclinical data showed PBFT02 improved lysosomal histopathology and reduced neuroinflammation in Grn knockout mice, and achieved widespread vector distribution throughout the nervous system in non-human primates Company delivered data during an oral presentation on Thursday, October 24 at ESGCT PHILADELPHIA, Oct. 24, 2024 (GLOBE NEWSWIRE) -- P

GlobeNewswire 5 months ago

PASG
-11.52%
Orbimed Advisors LLC Adjusts Stake in Passage Bio Inc

On September 19, 2024, Orbimed Advisors LLC, a prominent investment firm, executed a significant transaction involving the shares of Passage Bio Inc (NASDAQ:PASG). Despite this reduction, Orbimed Advisors LLC maintains a substantial position in Passage Bio, holding 12.62% of the company's shares, which represents 0.11% of their total portfolio. Founded in 1989, Orbimed Advisors LLC has grown into a global leader in healthcare investment, managing approximately $15 billion across various funds.

GuruFocus.com 6 months ago

PASG
-11.52%
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines Conference

PHILADELPHIA, Sept. 23, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will present at Chardan’s 8th Annual Genetic Medicines Conference on Tuesday, October 1, 2024 at 8:30 a.m. ET. A live webcast of the event will be available on the Investors & Media section of Passage Bio’s website at inv

GlobeNewswire 6 months ago

PASG
-11.52%
Orbimed Advisors LLC Reduces Stake in Passage Bio Inc

On September 18, 2024, Orbimed Advisors LLC executed a significant transaction by reducing its holdings in Passage Bio Inc (NASDAQ:PASG), a company focused on genetic medicines for CNS disorders. Founded in 1989, Orbimed Advisors LLC has grown from a public equity fund into a global leader with approximately $15 billion in assets under management. Orbimed has expanded its reach globally, with offices in Asia, the Middle East, and beyond, focusing on a variety of investment strategies including long/short equity and private equity.

GuruFocus.com 6 months ago

PASG
-11.52%
Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias (ISFTD2024)

Interim safety and biomarker data from the upliFT-D trial in FTD-GRN demonstrated that Dose 1 of PBFT02 achieved robust levels of CSF progranulin in all treated Cohort 1 patients; elevated CSF progranulin levels were sustained up to 12 months post-treatment Dose 1 of PBFT02 continued to be well-tolerated in all patients who received a revised immunosuppression regimen Company to deliver the updated data during a poster presentation at ISFTD2024 on Friday, September 20, 2024 at 9:38 a.m. GMT PHIL

GlobeNewswire 6 months ago

PASG
-11.52%
Passage Bio Welcomes Tom Kassberg to Board of Directors

PHILADELPHIA, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced the appointment of Tom Kassberg to the Board of Directors and his appointment to the Audit Committee. Mr. Kassberg is currently Chief Business Officer and Executive Vice President at Ultragenyx, a biopharmaceutical company committed to bringing novel therapies to patients for the t

GlobeNewswire 6 months ago

PASG
-11.52%
Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference

PHILADELPHIA, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that Will Chou, M.D., president and chief executive officer, will present at the H.C. Wainwright 26th Annual Global Investment Conference on Monday, September 9, 2024 at 7:00 a.m. ET. A live webcast of the event will be available on the Investors & Media section of Passage Bio’s web

GlobeNewswire 7 months ago

PASG
-11.52%
Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights

Enrolled first FTD-GRN patient in Cohort 2 in upliFT-D trial Plan to present updated safety and biomarker data from Cohort 1 FTD-GRN patients treated with PBFT02 at 14th International Conference on Frontotemporal Dementias (ISFTD2024) in September 2024 Achieved alignment with Food and Drug Administration (FDA) on the company's proposed clinical development plans to expand the upliFT-D trial to assess PBFT02 in FTD patients with C9orf72 gene mutations Completed out-licensing of pediatric lysosoma

GlobeNewswire 7 months ago

PASG
-11.52%
Jim Wilson, prominent gene therapy researcher, to depart UPenn

Wilson, who founded UPenn’s gene therapy program three decades ago, will step down to start two new spinouts, Gemma Bio and Franklin Biolabs.

BioPharma Dive 8 months ago

PASG
-11.52%
Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration

Granted exclusive, worldwide rights for the development and commercialization of PBGM01 for GM1 gangliosidosis, PBKR03 for Krabbe disease, and PBML04 for metachromatic leukodystrophy to GEMMA Biotherapeutics, a new company co-founded by Dr. James M. Wilson Entered new strategic research and collaboration agreement with GEMMA Biotherapeutics to advance genetic medicines for CNS indications, including Huntington’s disease Transaction expected to extend operating cash runway to the end of Q2 2026 P

GlobeNewswire 8 months ago

PASG
-11.52%

Performance Overview

Return	PASG	S&P 500 (^GSPC)
YTD	-36.17%	-10.43%
1-Year	-71.28%	+2.08%
3-Year	-88.80%	+17.37%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Live

Passage Bio, Inc. (PASG)

Passage Bio (PASG) Upgraded to Buy: Here's What You Should Know

Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights

Passage Bio to Participate in Upcoming Investor Conferences

Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates

Will Passage Bio (NASDAQ:PASG) Spend Its Cash Wisely?

Passage Bio assumed with an Outperform at Wedbush

Update: Wedbush Raises Price Target on Passage Bio to $4 From $3, Keeps Outperform Rating

Passage Bio Achieves Milestones in Gene Therapy Trials

Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights

Passage Bio to Present at Guggenheim Securities Healthcare Innovation Conference

Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference

Orbimed Advisors LLC Adjusts Stake in Passage Bio Inc

Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines Conference

Orbimed Advisors LLC Reduces Stake in Passage Bio Inc

Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias (ISFTD2024)

Passage Bio Welcomes Tom Kassberg to Board of Directors

Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference

Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights

Jim Wilson, prominent gene therapy researcher, to depart UPenn

Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration

Performance Overview